Please login to the form below

Not currently logged in


This page shows the latest Tasigna news and features for those working in and with pharma, biotech and healthcare.

FDA’s year-end approvals take annual tally to 46

FDA’s year-end approvals take annual tally to 46

Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... Patients with early (chronic) phase CML who have been taking Tasigna for three years or more and whose leukaemia has responded to

Latest news

More from news
Approximately 5 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). ... and Tasigna.

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There are also global direct-to-patient access programmes for Gleevec and Tasigna, life-saving therapies for chronic myeloid leukemia and gastrointestinal stromal tumours. ... Through the programmes, Gleevec and Tasigna were supplied to more than 42, 000

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...